IRWD IRONWOOD PHARMACEUTICALS INC

Nasdaq ironwoodpharma.com


$ 1.60 $ 0.13 (8.78 %)    

Wednesday, 15-Oct-2025 17:10:15 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 1.61
$ 1.54
$ 1.54 x 100
$ 1.65 x 26
$ 1.52 - $ 1.62
$ 0.53 - $ 5.13
1,001,860
na
261.52M
$ 0.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-16-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-17-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-30-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-25-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-06-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 02-22-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ironwood-pharmaceuticals-sees-fy2025-sales-260000m-290000m-vs-270600m-est

Ironwood Pharmaceuticals (NASDAQ:IRWD) sees FY2025 sales of $260.000 million-$290.000 million vs $270.600 million analyst estim...

 ironwood-pharmaceuticals-q2-adj-eps-014-beats-004-estimate-sales-85239m-beat-60775m-estimate

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate...

 wells-fargo-downgrades-ironwood-pharmaceuticals-to-equal-weight-lowers-price-target-to-1

Wells Fargo analyst Mohit Bansal downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Overweight to Equal-Weight and lower...

 jefferies-downgrades-ironwood-pharmaceuticals-to-hold-lowers-price-target-to-07

Jefferies analyst Amy Li downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) from Buy to Hold and lowers the price target from...

 leerink-partners-maintains-market-perform-on-ironwood-pharmaceuticals-lowers-price-target-to-1

Leerink Partners analyst Faisal Khurshid maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Market Perform and lowers t...

 ironwood-pharmaceuticals-stock-plunges-fda-wants-another-trial-for-gastrointestinal-drug

Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION